Status:
COMPLETED
Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40-99 years
Phase:
PHASE1
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® an...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Insulin naive
- No previous experience administering injections
Exclusion
- Any condition that, in the Investigator and/or Sponsor's opinion, could interfere with the results of this trial
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00127296
Start Date
July 1 2005
End Date
September 1 2005
Last Update
January 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78229